BioNTech Reports Q3 2026 Earnings with Profit Turnaround and Oncology Progress
BioNTech (BNTX) reported third-quarter revenue of EUR 1.3 billion, a decrease from the previous year's EUR 1.5 billion due to declining COVID-19 vaccine demand. Despite this, the company achieved a net profit of EUR 184.5 million, marking a significant turnaround from a net loss in the prior-year period. The company raised its full-year revenue guidance midpoint to a range of EUR 1.7 billion to EUR 1.9 billion. The company is aggressively pivoting toward oncology, supported by a robust cash position of EUR 16.2 billion. Key clinical highlights include strong efficacy data for Gotistobart in lung cancer and high objective response rates for the Pumitamig and Alpha-D combination in small cell lung cancer. While some trials, such as BNT113, missed primary endpoints, BioNTech continues to prioritize immuno-oncology and antibody-drug conjugate programs through strategic capital allocation.
Topics: clinical trial results guidance net profit revenue share repurchases
Read the full article at Motley Fool
Part of the story Manulife Reports Record Core Earnings and Strong Asian Growth in Q3 2026 (106 articles)